Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05301751Phase 2Completed

A Single Ascending Dose Cohort Study of AG-73305 in DME Patients

Role: lead

NCT05372107Phase 1Completed

A Study of AG-80308 in Dry Eye Patients

Role: lead

NCT03533244Phase 2Completed

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

Role: lead

All 3 trials loaded